Key facts
- Notable investors include Xlife Sciences.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Firstgene Life Sciences
- ·The full record, as it builds
Funding rounds
No funding rounds for Firstgene Life Sciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Firstgene Life Sciences
Developer of a targeted gene delivery therapy designed for precision treatment of hepatocellular carcinoma. The company's platform utilizes adeno-associated virus-like particles engineered for selective uptake by carcinoma cells, incorporates a novel primer compound for enhanced specificity, supports scalable manufacturing through molecular engineering and preclinical validation, and enables the oncology market improved therapeutic efficacy with reduced systemic side effects.
- Sector
- Healthcare
- HQ
- Mainz, Germany
- Founded
- 2025
- Website
- firstgene.de/
- Ownership
- Privately Held (backing)
Firstgene Life Sciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Firstgene Life Sciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Firstgene Life Sciences in its N-PORT filings yet. We sweep new filings monthly.